Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Infanrix hexa vs Infanrix penta + Hiberix in Healthy Infants
NCT01457508Phase 3Completed
- Sponsor
- GSK
- Start
- Jan 1999
- Primary completion
- Mar 2000
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
01
Overview
Phase 3, randomised, open-label trial of pertussis filamentous haemagglutinin in hepatitis B (HBV), diphtheria, Haemophilus influenzae type b infection (Hib) and 3 more (2 arms), sponsored by GSK. Primary endpoint: Immunogenicity with respect to the components of the study vaccine in terms of number of subjects with antibody titres greater than or equal to cut off value at Month 3. Started Jan 1999; status: completed.
02
Drugs
pertussis filamentous haemagglutinin
03
Conditions
hepatitis B (HBV)diphtheriaHaemophilus influenzae type b infection (Hib)poliomyelitispertussis
Beyond the preview
Go deeper on NCT01457508.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01457508.